Ovarian cancer trial uses KELIM score to personalize surgery timing
NCT ID NCT07382479
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether a blood test score (KELIM) can help doctors decide the best time for surgery in people with advanced ovarian cancer. After three rounds of chemotherapy, those with a good score will have surgery right away, while those with a poor score will get more chemo first. The goal is to see if this personalized approach improves overall survival.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EPITHELIAL OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Metabolic clues: could your Body's energy use predict ovarian cancer outcomes?
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- Can heated chemotherapy improve ovarian cancer outcomes?
- Can a new PET tracer light up hidden cancers?
- A Two-for-One surgery: could tube removal during Weight-Loss surgery slash ovarian cancer risk?
- Can AI spot ovarian cancer on CT scans before It's too late?